Skip to main content
. Author manuscript; available in PMC: 2021 Nov 24.
Published in final edited form as: Exp Hematol. 2021 Jul 21;100:1–11. doi: 10.1016/j.exphem.2021.07.002

Figure 1.

Figure 1.

Clinical and biological differences in CD28- and 4–1BB−containing CAR T cells. Second-generation CARs, consisting of an antigen-binding domain (scFv) connected via an extracellular and transmembrane domain to a co-stimulatory domain (derived from either CD28 or 4–1BB) and the intracellular portion of the CD3z chain. Both CAR formats successfully activate T cells leading to leukemic clearance in preclinical models and in patients; however, each co-stimulatory molecule elicits differences in persistence, T-cell phenotype, and metabolism.